SA519401954B1 - تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد - Google Patents
تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويدInfo
- Publication number
- SA519401954B1 SA519401954B1 SA519401954A SA519401954A SA519401954B1 SA 519401954 B1 SA519401954 B1 SA 519401954B1 SA 519401954 A SA519401954 A SA 519401954A SA 519401954 A SA519401954 A SA 519401954A SA 519401954 B1 SA519401954 B1 SA 519401954B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- preventing
- pharmaceutical composition
- treating cancer
- crystalline polymorph
- tetraarsenic hexoxide
- Prior art date
Links
- UYVQXFOBKTWZCW-UHFFFAOYSA-N tetraarsenic Chemical compound [As]12[As]3[As]1[As]32 UYVQXFOBKTWZCW-UHFFFAOYSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
- C01G28/005—Oxides; Hydroxides; Oxyacids
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/60—Compounds characterised by their crystallite size
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
يتعلق الاختراع الحالي بتركيبة صيدلانية للوقاية من أو معالجة السرطان cancer وطريقة لإنتاجها، وتشتمل التركيبة على هيكسوكسيد تتراسينيك tetraarsenic hexoxide وحيث يكون به محتوى الصورة متعددة الأشكال المتبلرة أ (As4O6-a ) هو 99٪ أو أكثر. وتعرض تركيبة الاختراع الحالي تأثير تثبيط تكاثر خلية السرطان cancer cell وبالتالي يمكن أن تكون مفيدة في شكل عقار مضاد للسرطان anticancer drug. شكل10
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160167222A KR101844050B1 (ko) | 2016-12-09 | 2016-12-09 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| PCT/KR2017/014082 WO2018105972A1 (ko) | 2016-12-09 | 2017-12-04 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519401954B1 true SA519401954B1 (ar) | 2024-01-29 |
Family
ID=62187734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519401954A SA519401954B1 (ar) | 2016-12-09 | 2019-06-09 | تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11191779B2 (ar) |
| EP (1) | EP3552611A4 (ar) |
| JP (1) | JP6824409B2 (ar) |
| KR (1) | KR101844050B1 (ar) |
| CN (2) | CN108606979A (ar) |
| AU (1) | AU2017371040B2 (ar) |
| BR (1) | BR112019010999A2 (ar) |
| CA (1) | CA3044514C (ar) |
| CL (1) | CL2019001565A1 (ar) |
| IL (1) | IL267132B (ar) |
| MX (1) | MX2019006622A (ar) |
| MY (1) | MY197417A (ar) |
| PH (1) | PH12019501292A1 (ar) |
| SA (1) | SA519401954B1 (ar) |
| WO (1) | WO2018105972A1 (ar) |
| ZA (1) | ZA201903059B (ar) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| DK3788047T3 (da) | 2018-05-04 | 2024-09-16 | Incyte Corp | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102240693B1 (ko) * | 2020-05-18 | 2021-04-15 | 주식회사 케마스 | 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1378240T3 (da) | 1997-10-15 | 2008-12-08 | Polarx Biopharmaceuticals Inc | Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom |
| ES2399480T3 (es) * | 1997-11-10 | 2013-04-01 | Memorial Sloan-Kettering Cancer Center | Procedimiento de producción de formulaciones de trióxido de arsénico |
| KR100272835B1 (ko) | 1998-05-08 | 2000-11-15 | 배일주 | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 |
| US7261906B2 (en) | 1998-05-08 | 2007-08-28 | Ill-Ju Bae | Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition |
| DE19821508C2 (de) | 1998-05-13 | 2002-08-29 | Trelleborg Automotive Tech Ct | Zweikammer-Motorlager |
| KR20020095835A (ko) | 2001-06-16 | 2002-12-28 | 배일주 | 아폽토시스 유도제 |
| TWI296527B (en) | 2003-04-23 | 2008-05-11 | Inst Of Nuclear Energy Res Rocaec | Radioactive aesenic-containing compounds and their uses in the treatment of tumors |
| US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| KR101572529B1 (ko) | 2008-11-14 | 2015-11-27 | 배일주 | 암 치료를 위한 육산화사비소의 병용요법 |
| EP3981414A1 (en) | 2015-02-01 | 2022-04-13 | Syros Pharmaceuticals, Inc. | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| KR101755556B1 (ko) | 2016-11-18 | 2017-07-07 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR101834366B1 (ko) * | 2016-11-21 | 2018-03-05 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR101844049B1 (ko) | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
-
2016
- 2016-12-09 KR KR1020160167222A patent/KR101844050B1/ko active IP Right Grant
-
2017
- 2017-03-06 CN CN201710127742.4A patent/CN108606979A/zh active Pending
- 2017-03-06 CN CN202310686518.4A patent/CN116672363A/zh active Pending
- 2017-12-04 US US16/467,593 patent/US11191779B2/en active Active
- 2017-12-04 MY MYPI2019003009A patent/MY197417A/en unknown
- 2017-12-04 MX MX2019006622A patent/MX2019006622A/es unknown
- 2017-12-04 CA CA3044514A patent/CA3044514C/en active Active
- 2017-12-04 BR BR112019010999A patent/BR112019010999A2/pt unknown
- 2017-12-04 EP EP17878772.7A patent/EP3552611A4/en active Pending
- 2017-12-04 JP JP2019529224A patent/JP6824409B2/ja active Active
- 2017-12-04 AU AU2017371040A patent/AU2017371040B2/en active Active
- 2017-12-04 WO PCT/KR2017/014082 patent/WO2018105972A1/ko unknown
-
2019
- 2019-05-16 ZA ZA2019/03059A patent/ZA201903059B/en unknown
- 2019-06-06 IL IL267132A patent/IL267132B/en unknown
- 2019-06-07 PH PH12019501292A patent/PH12019501292A1/en unknown
- 2019-06-07 CL CL2019001565A patent/CL2019001565A1/es unknown
- 2019-06-09 SA SA519401954A patent/SA519401954B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267132B (en) | 2022-05-01 |
| JP6824409B2 (ja) | 2021-02-03 |
| ZA201903059B (en) | 2020-09-30 |
| CA3044514C (en) | 2021-06-15 |
| CN116672363A (zh) | 2023-09-01 |
| US20200000846A1 (en) | 2020-01-02 |
| CA3044514A1 (en) | 2018-06-14 |
| BR112019010999A2 (pt) | 2019-10-15 |
| EP3552611A1 (en) | 2019-10-16 |
| CL2019001565A1 (es) | 2020-02-21 |
| US11191779B2 (en) | 2021-12-07 |
| WO2018105972A1 (ko) | 2018-06-14 |
| MY197417A (en) | 2023-06-16 |
| EP3552611A4 (en) | 2020-06-24 |
| KR101844050B1 (ko) | 2018-05-14 |
| AU2017371040B2 (en) | 2020-05-07 |
| CN108606979A (zh) | 2018-10-02 |
| AU2017371040A1 (en) | 2019-06-20 |
| MX2019006622A (es) | 2019-08-01 |
| PH12019501292A1 (en) | 2019-12-02 |
| JP2020504088A (ja) | 2020-02-06 |
| IL267132A (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401954B1 (ar) | تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد | |
| PH12019501220A1 (en) | Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| SA519401785B1 (ar) | تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها | |
| SA519401787B1 (ar) | تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
| SA520411108B1 (ar) | مركبات حلقية كبيرة واستخداماتها | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| MX2022000517A (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr). | |
| MX2015015144A (es) | Potenciador de inhibidores del homologo de zeste. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| MY179141A (en) | Dipicolylamine derivatives and their pharmaceutical uses | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| WO2016126073A3 (ko) | 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 암 줄기세포의 성장 억제용 약학적 조성물 | |
| TH1901003032A (th) | องค์ประกอบทางเภสัชกรรมสำหรับการป้องกันหรือการรักษาโรคมะเร็งเต้านมที่ประกอบด้วยสารพหุสัณฐานรูปผลึกของเตตระอาร์ซีนิกเฮกซ์ออกไซด์และวิธีการสำหรับการผลิตสิ่งเดียวกันนี้ | |
| IN2014MU00666A (ar) |